ArticleKidney medicine2026
Rifampin-induced Acute Kidney Injury Is Associated With Hemolysis and Drug Re-exposure.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Acute kidney injury and hemolysis are rare side effects of rifampin that are sometimes linked with drug re-exposure. We studied this association in a contemporary patient cohort to comprehensively correlate the clinical, laboratory, and biopsy findings. Study Design: Adult patients who underwent kidney biopsy for acute kidney injury while on rifampin during an 11-year period (2012-2023) were identified. Electronic medical records and biopsy pathology were correlated. Setting & Participants: Eighteen patients (50% men, ages 43-81) were prescribed rifampin for active pulmonary tuberculosis (7), latent tuberculosis (3), Results: Patients most commonly presented with gastrointestinal and 'flu-like' symptoms, 1 day to 1 month after rifampin (re-)exposure. Creatinine at biopsy was 2.2-26.1 mg/dL. Importantly, 15 patients had evidence of hemolysis. All biopsies demonstrated acute tubular injury, yet inflammation (acute interstitial nephritis) was variable. Eleven had pigmented casts, 9 with hemoglobin and 2 with myoglobin. Thus, we highlight acute tubular necrosis with hemoglobin casts as a major finding in rifampin kidney injury. Management included supportive care, steroids, and discontinuation of rifampin. Eleven patients required hemodialysis. Fifteen patients had complete renal remission. Limitations: Retrospective case series without uniformly available clinical and laboratory data. Conclusions: Hemolytic anemia, hemoglobin cast nephropathy, and acute kidney injury are rare but serious complications of rifampin. Clinicians and patients should be aware of this side effect, and interrupted use of rifampin therapy should be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.